FLSM
GPCR icon

Frazier Life Sciences Management’s Structure Therapeutics GPCR Stock Holding History

Frazier Life Sciences Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-629,194
Closed -$27M – 53
2024
Q1 		$27M Buy
629,194
+312,004
+98% +$13.2M 1.14% 26
2023
Q4 		$12.9M Buy
+317,190
New +$18.2M 0.69% 37

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Frazier Life Sciences Management's GPCR Position: Q2 2024 in Review

Frazier Life Sciences Management sold out of Structure Therapeutics (GPCR) in Q2 2024, closing a stake of 629,194 shares — an estimated $27M sold.

Frazier Life Sciences Management first reported a position in GPCR in Q4 2023 and held it in 2 quarters. The position peaked at $27M in Q1 2024. 166 funds tracked by Wall St. Rank hold GPCR as of Q2 2024.

  • Frazier Life Sciences Management reported no remaining Structure Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Frazier Life Sciences Management sold 629,194 Structure Therapeutics shares in Q2 2024, an estimated $27M.
  • Frazier Life Sciences Management first reported a position in Structure Therapeutics in Q4 2023 and held it in 2 quarters.
  • Frazier Life Sciences Management's Structure Therapeutics position peaked at $27M in Q1 2024.
  • 166 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2024.

Based on Frazier Life Sciences Management's 13F filing for Q2 2024, filed 15 Aug 2024.